Tseng A.,National Central University |
Yang C.-H.,National Chung Hsing University |
Chen C.-H.,National Central University |
Chen C.-H.,Kaohsiung Chang Gung Memorial Hospital |
And 9 more authors.
Oncology Reports | Year: 2016
The fact that many chemotherapeutic drugs cause chemoresistance and side effects during the course of colorectal cancer treatment necessitates development of novel cytotoxic agents aiming to attenuate new molecular targets. Here, we show that Astragalus membranaceus (Fischer) Bge. var. mongolicus (Bge.) Hsiao (AM), a traditional Chinese medicine, can inhibit tumor growth in vivo and elucidate the underlying molecular mechanisms. The antitumor effect of AM was assessed on the subcutaneous tumors of human colorectal cancer cell line HCT116 grafted into nude mice. The mice were treated with either water or 500 mg/kg AM once per day before being sacrificed for extraction of tumors, which were then subjected to microarray expression profiling. The gene expression of the extraction was then profiled using microarray analysis. The identified genes differentially expressed between treated mice and controls reveal that administration of AM suppresses chromosome organization, histone modification and regulation of macromolecule metabolic process. A separate analysis focused on differentially expressed microRNAs revealing involvement of macromolecule metabolism, and intracellular transport, as well as several cancer signaling pathways. For validation, the input of the identified genes to The Library of Integrated Network-based Cellular Signatures led to many chemopreventive agents of natural origin that produce similar gene expression profiles to that of AM. The demonstrated effectiveness of AM suggests a potential therapeutic drug for colorectal cancer.
Liang Z.,Shandong University |
Liang Z.,Yantaishan Hospital |
Sun X.-Y.,Reproductive Medical Center |
Xu L.-C.,Yantaishan Hospital |
Fu R.-Z.,Qianfoshan Hospital
Medical Science Monitor | Year: 2014
Background: Increased amounts of soluble E-cadherin (E-cad) have been found in the serum in various cancers, but the role of serum soluble E-cad in the prognosis of breast cancer patients has not been explored in Asian populations. Material/Method: Blood samples from 111 consecutive patients diagnosed with breast cancer and 55 healthy controls were in-vestigated. Serum soluble E-cad expression levels were measured by enzyme-linked immunosorbent assay (ELISA) with an immunoassay kit according to the manufacturer’s directions. Kaplan-Meier analyses were used to evaluate the association between serum soluble E-cad expression level and survival. All statistical tests were 2-sided. Results: The serum levels of soluble E-cad in breast cancer patients were significantly higher than those of the control group (2218.9±319.6 ng/ml vs. 742.8±91.7 ng/ml, p<0.001). Serum levels of soluble E-cad correlated signifi- cantly with TNM stage (P=0.007), tumor grade (P=0.03), and lymph node metastasis (P<0.001). Kaplan-Meier analysis with the log-rank test indicated that high serum levels of soluble E-cad had a significant impact on overall survival (55.4% vs. 81.4%; P=0.032) and disease-free survival (36.8% vs. 67.8%; P=0.002) in breast can- cer. Multivariate analysis revealed that serum levels of soluble E-cad were independently associated with over-all survival and disease-free survival in breast cancer patients. Conclusions: Serum soluble E-cad level is an independent prognostic factor in Asian breast cancer patients. © Med Sci Monit, 2014; 20: 2776-2782.
Fang L.,Reproductive Medical Center |
Fang L.,Zhengzhou University |
Cheng J.-C.,Zhengzhou University |
Chang H.-M.,Zhengzhou University |
And 2 more authors.
Journal of Clinical Endocrinology and Metabolism | Year: 2013
Context: Aberrant regulation of ovulation isoneof the major causes of infertility. In animal models, 3 epidermal growth factor (EGF)-like growth factors, amphiregulin (AREG), betacellulin (BTC), and epiregulin (EREG), have been shown to be involved in ovulation by regulating cyclooxygenase-2 (COX-2) expression and prostaglandin E2 (PGE2) production. However, whether the same is true in humans remains largely unknown. Objective:Our objective was to investigate the effects of AREG, BTC, and ERE Gon COX- 2 expression and PGE 2 production in human granulosa cells. Design and Setting: SVOG cells are human granulosa cells that were obtained from women undergoing in vitro fertilization and immortalized with SV40 large T antigen. SVOG cells were used to investigate the effect of AREG, BTC, and EREG on ovulation-related functions at an academic research center. Main Outcome Measures: Levels of mRNA and protein were examined by quantitative RT-PCR and Western blotting, respectively. The protein levels of PGE2 were measured by ELISA. Results: LH treatment upregulated AREG, BTC, EREG, and COX-2. Knockdown of EGF receptor (EGFR) attenuated LH-induced COX-2 expression and PGE2 production. Treatment with AREG, BTC, and EREG upregulated COX-2 expression and PGE2 production. The stimulatory effects of AREG, BTC, and EREG on COX-2 expression and PGE2 production were blocked by inhibition of EGFR activity and expression. AREG-, BTC-, and EREG-activated ERK1/2 signaling, but not Akt signaling, was required for AREG-, BTC-, and EREG-induced COX-2 expression and PGE2 production. Conclusion: AREG, BTC, and EREG induced PGE2 production by upregulating COX-2 expression through ERK1/2 signaling in human granulosa cells. © 2013 by The Endocrine Society.
Ding C.,Reproductive Medical Center |
Huang S.-J.,Reproductive Medical Center |
Zhao S.-Q.,Reproductive Medical Center
Journal of Reproduction and Contraception | Year: 2012
Objective: To analyze the clinical features and outcomes in infertile patients with different levels of thyroid stimulating hormone (TSH) undergoing IVF/ICSI, and to investigate whether inappropriate level of TSH has the adverse effect on the results of the IVF-ET. Methods: A total of 389 patients undergoing IVF/ICSI from January 2009 to December 2011 were divided into 3 groups according to the basal TSH level: group A (TSH< 2.0 mIU/L), group B (TSH 2.0-4.5 mIU/L) and group C (TSH>4.5 mIU/L). Oocyte retrieved, fertilization rate, cleavage rate, available embryo rate, pregnancy rate and miscarriage rate were analyzed to explore whether serum TSH level was correlated with the results of IVF/ICSI. Results: There were no differences in number of oocyte retrieved, fertilization rate, cleavage rate and available embryo rate among 3 groups (P>0.05). Clinical pregnancy rate in group B (43.0%) was significantly higher than that in group A (30.2%) and group B (23.5%), respectively (P<0.05). There were no significant differences in miscarriage rate among 3 groups. Conclusions: TSH level has no effect on fertility rate or miscarriage rate in patients undergoing IVF/ICSI. Inadequacy TSH level would decrease the IVF/ICSI pregnancy rate. © 2012 The Editorial Board of Journal of Reproduction and Contraception.